Arrowstreet Capital, Limited Partnership Argenx Se Transaction History

Arrowstreet Capital, Limited Partnership

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$269.58 - $378.88 $461,520 - $648,642	-1,712 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$254.45 - $351.06 $435,618 - $601,014	1,712 New	1,712 $540,000
Q3 2020 Nov 12, 2020	SELL	$215.51 - $272.51 $1.16 Million - $1.47 Million	-5,400 Closed	0 $0
Q2 2020 Aug 12, 2020	SELL	$127.44 - $232.72 $409,847 - $748,427	-3,216 Reduced 37.33%	5,400 $1.22 Million
Q1 2020 May 15, 2020	SELL	$108.83 - $165.23 $6.12 Million - $9.29 Million	-56,251 Reduced 86.72%	8,616 $1.14 Million
Q4 2019 Feb 13, 2020	BUY	$106.59 - $164.21 $6.91 Million - $10.7 Million	64,867 New	64,867 $10.4 Million
Q4 2018 Feb 14, 2019	SELL	$63.81 - $109.82 $574,290 - $988,379	-9,000 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$75.5 - $96.63 $679,500 - $869,670	9,000 New	9,000 $683,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.9B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.